Scholar Rock Holding eyes key EMA decision, shares trade higher on NASDAQ
23.06.2026 - 17:36:12 | ad-hoc-news.de
By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 17:32.
Scholar Rock Holding (US8063231019) is drawing investor attention as shares trade on NASDAQ close to recent highs, while the next regulatory milestones for its lead SMA therapy approach. A scheduled EMA review decision on June 30, 2026 stands out as a near-term date for the stock, according to event data from StockTitan.
Regulatory calendar in focus
Event trackers list an “EMA review decision” for Scholar Rock Holding on June 30, 2026, highlighting a key European regulatory milestone for the company’s spinal muscular atrophy candidate apitegromab. StockTitan event overview This comes on top of a US Food and Drug Administration PDUFA action date on September 30, 2026 following the recent resubmission of the biologics license application.
According to Simply Wall St, Scholar Rock recently resubmitted its apitegromab BLA with two fill-finish partners included, and the stock moved higher after the announcement, with a fresh September 30, 2026 PDUFA date now guiding expectations. Simply Wall St analysis of the BLA resubmission This dual supply strategy is designed to reduce operational risk around potential launch.
Analyst estimates and recent earnings
Consensus data collected by MarketBeat show that Scholar Rock released its first quarter 2026 numbers on May 7, 2026, reporting earnings per share of -0.83 US dollars versus an analyst consensus of -0.82 US dollars. MarketBeat earnings overview The miss of 0.01 US dollars per share underlines that the investment case remains dominated by pipeline and regulatory catalysts rather than near-term profitability.
Simply Wall St highlights that Scholar Rock’s Q1 2026 net loss reached roughly 105.5 million US dollars, reflecting increased spending ahead of a potential apitegromab approval. Simply Wall St analysis of financials and forecasts The same analysis cites internal forecasts that project revenue of about 398.1 million US dollars and earnings of 43.4 million US dollars by 2029, from a current earnings base of approximately -377.9 million US dollars.
All news and analysis on the Scholar Rock Holding shares
Regulatory dates, analyst estimates and price data on Scholar Rock Holding are compiled in the dedicated topic section and on the company’s Investor Relations page.
The product behind the stock
Scholar Rock’s lead product candidate is apitegromab, a monoclonal antibody targeting latent myostatin for the treatment of spinal muscular atrophy. The resubmitted biologics license application now references two fill-finish facilities to secure launch supply redundancy, according to Simply Wall St’s summary of recent company disclosures.
Where the stock trades today
The Scholar Rock Holding shares (US8063231019) last closed on NASDAQ at 51.34 US dollars on 2026-06-23, 10:32 Eastern time, according to StockTitan’s price overview, with a market capitalization in the mid single-digit billion US dollar range at that time.
Key data on the Scholar Rock Holding shares
- Company: Scholar Rock Holding Corp.
- ISIN: US8063231019
- WKN: A2N9Z8
- Ticker: SRRK
- Trading venue: NASDAQ
- Price (as of 2026-06-23, 10:32): 51.34 USD
- Market cap: approximately 5.9 billion USD (as of 2026-06-22)
- Sector / industry: Biotechnology / Pharmaceuticals
- Index membership: not a constituent of the S&P 500 or NASDAQ-100
- Next earnings date: not officially scheduled
This article is for information purposes only and does not constitute investment advice, investment recommendation or an offer to buy or sell securities. Figures and dates are based on sources cited in the text and may change. Investors should consult professional advisers before making investment decisions.
